<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20053">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845843</url>
  </required_header>
  <id_info>
    <org_study_id>KingAbdullahIMRC</org_study_id>
    <nct_id>NCT02845843</nct_id>
  </id_info>
  <brief_title>MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b</brief_title>
  <acronym>MIRACLE</acronym>
  <official_title>MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdullah International Medical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Abdullah International Medical Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled clinical trial to assess the feasibility, efficacy and safety
      of a combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with
      MERS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate the feasibility , efficacy and safety of lopinavir
      /ritonavir and recombinant Interferon beta-1b combination given with optimal supportive care
      compared to placebo with optimal supportive care for patients with laboratory-confirmed
      MERS-CoV infection requiring hospital admission.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90-day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Organ support-free days (e.g., supplemental O2, ventilator, extracorporeal membrane oxygenation (ECMO), renal replacement and vasopressors)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RT-PCR cycle threshold value in the lower respiratory samples</measure>
    <time_frame>At randomization and every 3 days afterwards, until 3 consecutive samples are negative or reaching a maximum of 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment (SOFA) scores</measure>
    <time_frame>Days 1, 3, 5, 7, 14, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>Up to one year from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>Up to one year from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Up to one year from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-acquired infections as assessed by the NHSN 2016 definitions</measure>
    <time_frame>Up to one year from enrollment</time_frame>
    <description>Infections will be reported as per the NHSN 2016 definitions, as number of events per devise day or ICU day as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial chest radiograph findings</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse drug reactions related to the treatment</measure>
    <time_frame>From enrollment to 28 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Scale</measure>
    <time_frame>90-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Up to one year from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Up to one year from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</condition>
  <arm_group>
    <arm_group_label>Combination of Lopinavir /Ritonavir and IntErferon Beta 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of Lopinavir /Ritonavir and Interferon beta-1b</intervention_name>
    <description>Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days</description>
    <arm_group_label>Combination of Lopinavir /Ritonavir and IntErferon Beta 1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients who are laboratory confirmed (RT-PCR) MERS-CoV and require hospital
             admission because of illness severity.

          2. More than or equal to 18 years of age.

        Exclusion criteria:

          1. History of acute severe neuropsychiatric disorder such as schizophrenia etc.

          2. History of hypersensitivity reaction to lopinavir /ritonavir, or any component of the
             formulation and to recombinant interferon beta-1b (e.g., toxic epidermal necrolysis,
             Stevens-Johnson syndrome, erythema multiforme, urticaria, angioedema)

          3. Fulminant liver failure

          4. Patients on medications which are contraindicated with the study drug and cannot be
             replaced or stopped during the study period (e.g Cytochrome P450 3A4 (CYP3A)
             inhibitors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yaseen Arabi, MD</last_name>
    <phone>+966-11-8011111</phone>
    <phone_ext>18855</phone_ext>
    <email>yaseenarabi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs</name>
      <address>
        <city>Riyadh</city>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaseen M Arabi, MD</last_name>
      <phone>+966(11)8011111</phone>
      <phone_ext>18855</phone_ext>
      <email>yaseenarabi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yaseen M Arabi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Abdullah International Medical Research Center</name>
      <address>
        <city>Riyadh</city>
        <zip>22490</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaseen Arabi, MD, FCCP, FCCM</last_name>
      <phone>966-11-8011111</phone>
      <phone_ext>18899</phone_ext>
      <email>arabi@ngha.med.sa</email>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 28, 2016</lastchanged_date>
  <firstreceived_date>June 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Middle East Respiratory Syndrome Coronavirus</keyword>
  <keyword>MERS-CoV</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Lopinavir</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Interferon beta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
